Please login to the form below

Not currently logged in
Email:
Password:

muscle disease

This page shows the latest muscle disease news and features for those working in and with pharma, biotech and healthcare.

Summit plunges after Duchenne disappointment

Summit plunges after Duchenne disappointment

However while this clinical trial failure was once typical of the DMD field, there are signs of a breakthrough against the life-shortening muscle wasting disease.

Latest news

  • Sarepta soars on positive Duchenne data Sarepta soars on positive Duchenne data

    the muscle wasting disease. ... DMD – a rare muscle-wasting disease that mostly affects boys and typically is fatal by age 30 – is caused by a defect in the gene coding for dystrophin, a protein found

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    ex-US rights to Spark Therapeutics’recently-approved Luxturna (voretigene neparvovec-rzyl) for an inherited eye disease. ... Last year, Biogen secured approval for the first drug treatment for SMA, a progressive, debilitating muscle-wasting disease

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    Trust. Spinraza (nusinersen) became the first drug to be approved for the often-fatal genetic disease, which affects muscle strength and movement, last May but its review by NICE has been ... However, it adds: “there is concern that this route is not

  • Biogen wins European spinal muscular atrophy first Biogen wins European spinal muscular atrophy first

    Biogen now has approval in Europe to go with its US license for Spinraza, its drug for the genetic disease spinal muscular atrophy (SMA). ... cases of the progressive, debilitating muscle-wasting disease.

  • FDA clears new ALS drug Radicava ahead of schedule FDA clears new ALS drug Radicava ahead of schedule

    Patients with the chronic neurodegenerative disease amyotrophic lateral sclerosis (ALS) have a new treatment option in the US after the FDA approved Mitsubishi Tanabe Pharma's Radicava (edaravone). ... ALS is a form of motor neuron disease (MND) which

More from news
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo

  • Astellas: Ten years young Astellas: Ten years young

    The two new areas the company has publicly said it will be focusing on are ophthalmology and muscle disease, along with the further development of some internal compounds in ophthalmology. ... option, while in muscle disease Astellas is working with

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics